If you have been reading about LC-MS and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
The intense sociality of humans and the readiness with which they perceive, and identify with, manifestations of physical pain in others have made the study of pain notoriously difficult to quantify. Indeed, many investigators of animal pain shy away from the use of the word "pain" in published research. They consider the term to be unscientific and grounded in human emotion, preferring others such as "stress" or "avoidance". As the subjective experience of animals is very resistant to rational assessment, the subjective difference between their painless reflex responses to noxious stimuli (nociception) and pain as humans understand it has been nearly impossible to determine conclusively. For this reason, essentially all scientific research into the nature of animal pain has depended upon so-called pain proxies. These include obvious behavioral changes—shying away, stamping, vocalization, ear cues etc.—as well as subtler changes, as when injured chickens or rats choose a feed that has been laced with an analgesic over feed that has not. Most prized by scientists are the quantifiable physiological changes such as elevated heart rate, wound temperature or stress hormone serum concentrations. These physiological proxies are valued because their assessments are carried out by machines and do not rely on humans to determine the magnitude of the variable under study. This is seldom the case for behavioral pain proxies, which are most often scored by a researcher on some numerical scale ranging from "no response" to "intense response".
Spelt, being closely related to bread wheat, is a likely source of alleles to increase wheat's genetic diversity, and so improve crop yields. Analysis of the Oberkulmer cultivar of spelt found 40 alleles that could contribute to increased yield. Among the differences were spelt's larger grain size, greater fertility of tillers, and longer fruiting spikes. Pm5 is an effector-triggered resistance gene for powdery mildew.
=== Regulation of actomyosin interactions === cMyBP-C regulates the positioning of myosin and actin for interaction and acts as a tether to the myosin S1 heads, limiting their mobility. This results in a decreased number of crossbridges formed, which hinders force generation, due to its N-terminal C1-M-C2 region interacting with the myosin-S2 domain. Furthermore, cMyBP-C contributes to the regulation of cardiac contraction at short sarcomere length and is required for complete relaxation in diastole.
catalyst Any element or compound that facilitates an increase in the rate of a chemical reaction but which is not consumed or destroyed during the reaction. It is considered both a reactant and a product of the reaction.
Sources: en.wikipedia.org
=== Cocaine === Cocaine, in contrast to marijuana or alcohol, is a powerful stimulant. Upon entering the bloodstream, it rapidly reaches the brain within minutes, causing a significant surge in dopamine levels. The effects of cocaine are intense but short-lived, typically lasting about 30 minutes. The primary method of administration is through nasal insufflation (snorting), although it can also be smoked in crystal rock form. The rapid increase in dopamine levels during use contributes to a pronounced and challenging comedown, often prompting individuals to seek higher doses in subsequent use to achieve the same effects as experienced previously. This pattern can contribute to the development of addiction. The effects of cocaine use include increased energy and euphoria, accompanied by potential negative effects such as paranoia, rapid heart rate, and anxiety, among others.
== UK appliance safety recalls == Following its 2014 acquisition of Indesit, Whirlpool identified a fire risk affecting certain vented and condensing tumble dryers sold in the United Kingdom under the Hotpoint, Indesit, Creda, Swan and Proline brands. The affected models had been manufactured between April 2004 and September 2015; lint could accumulate and come into contact with a heating element, creating a fire risk. Whirlpool told the House of Commons Business, Energy and Industrial Strategy Committee that 5.3 million affected machines had been manufactured for the UK market. Whirlpool began a modification programme in November 2015 rather than a full recall. Owners were initially advised that affected dryers could continue to be used under specified precautions, but the advice was changed in early 2017 to tell consumers not to use unmodified machines. In August 2016, a fire at Shepherds Court in Shepherd's Bush was attributed by the London Fire Brigade to an Indesit tumble dryer covered by Whirlpool's corrective-action programme. A House of Commons committee later criticised the decision not to initiate a full recall and the pace of the modification programme. In April 2019, the Office for Product Safety and Standards (OPSS) concluded that the risk of harm or injury from lint fires in dryers that had been modified was low, but required Whirlpool to improve aspects of its risk management and communication with consumers. Following further intervention by OPSS, Whirlpool agreed in July 2019 to recall remaining unmodified affected tumble dryers.
=== Traditional coloring with three primaries === The first known case of trichromacy coloration (of 3 primaries) can be found in a work on optics by the Belgian thinker Franciscus Aguilonius in 1613, who in his "Opticorum libri sex, philosophis iuxtà ac mathematicis utiles" in Latin (Roughly, Six books of optics: useful to philosophers as well as to mathematicians), graphed the colors flavvus, rvbevs and cærvlevs (yellow, red and blue) giving rise to the intermediate colors avrevs, viridis and pvrpvrevs (orange, green and purple) and their relationship with the extremes albvs and niger (white and black). However, the idea of three primary colors is older, as Aguilonius supported the view known since the Middle Ages that the colors yellow, red, and blue were the basic or "noble" colors from which all others are derived. This model was used for printing by Jacob Christoph Le Blon in 1725 and called it Coloritto or harmony of colouring, stating that the primitive (primary) colors are yellow, red and blue, while the secondary are orange, green and purple, or violet. In 1766, Moses Harris developed an 18-color color wheel based on this model, including a wider range of colors by adding light and dark derivatives.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.